Varda Space, a US space startup, has raised $250 million in a new Series D round at a valuation of $1.6 billion. The company shared the news with Reuters on September 30, 2026.
The new capital takes Varda’s total funds raised since its 2021 launch to $598 million. The latest round was led by Lux Capital and Natural Capital. The company plans to use the fresh money to expand its work in space, with a strong focus on drug production in microgravity.
Varda is based in El Segundo, California. Its main idea is simple but very unusual. The company wants to use space as a place where certain products can be made in ways that are hard to achieve on Earth.
Its main focus is medicine. Varda wants to make certain drugs in space and then bring them back to Earth. The company believes that low gravity can help create better forms of some medicines.
A new kind of space factory
Most people think of space companies as businesses that build rockets, satellites or spacecraft. Varda has a different plan.
The company builds small, uncrewed capsules that can act as laboratories and factories in orbit. These capsules can carry materials away from Earth, spend time in space and then return to Earth.
The idea behind this system is based on the special conditions found in microgravity. On Earth, gravity can affect how materials mix, form crystals and behave during production. In space, those effects can be much lower.
That difference may help companies create some materials with better purity or better structure. Varda sees pharmaceuticals as one of the most valuable uses for this technology.
The company has also used its capsules for other work. Its vehicles can carry research payloads for government agencies and private customers. Some missions also support research linked to hypersonic technology.
Six missions have reached orbit
Varda has already moved beyond the early research stage. Since 2023, the company has sent six missions into orbit with its W-Series capsule.
The capsule has a distinctive shape and can work as a free-flying laboratory in space. After its work in orbit, it can return through Earth’s atmosphere and bring its cargo back to the ground.
Five of the company’s first six missions successfully returned from space. The company also plans to introduce a new generation of its capsule in 2030.
This record matters because space manufacturing is not just about putting a machine into orbit. A company also needs a safe way to bring the product back to Earth.
That return stage can be one of the hardest parts of the process. The capsule has to survive very high heat and extreme speed as it passes through the atmosphere.
Varda says its latest capsules can return at about 25 times the speed of sound. This gives the company another possible source of business because the same vehicles can support hypersonic tests.
Two capsules set for a major mission
Varda also has plans for an important mission that will send two capsules into space at the same time.
The launch is set to use a SpaceX Falcon 9 rocket. The capsules will carry hypersonic research payloads for the Pentagon and commercial customers.
This is a notable step for Varda because its business is not limited to one type of customer. Government agencies are already an important part of its customer base, while pharmaceutical companies are expected to become a larger part of the business over time.
Reuters reported that about 70% of Varda’s payload customers for next year are expected to come from the government sector. The rest are expected to come from commercial pharmaceutical work.
Varda CEO Will Bruey expects this mix to change. By 2032, he expects commercial pharmaceutical work to make up a much larger share of the company’s business.
Why drug production matters
The pharmaceutical side of Varda’s plan is the most ambitious part of its business.
Making a drug on Earth is a complex process. Scientists must control many factors so that the final product has the right form, purity and performance.
Microgravity can change how materials behave. For some medicines, that may create a useful form that is difficult or expensive to make on Earth.
Varda is therefore not trying to make ordinary products in space simply because it can. Its goal is to focus on products where space conditions may provide a real advantage.
The company hopes one of its biggest milestones will come near the end of this decade. Bruey told Reuters that the company wants to reach a point where a formulation created with the help of microgravity can enter human clinical trials.
That would be a major change for the business. It would show that a product made through a space-based process can move toward real medical use on Earth.
Varda wants more pharmaceutical expertise
The company has also added people with strong experience in the pharmaceutical sector.
In August, Varda appointed Mikael Dolsten to its board. Dolsten is a former Pfizer executive with a long career in biotechnology and drug research. His experience gives Varda a stronger link to the pharmaceutical industry.
Varda also has a large group of employees with pharmaceutical backgrounds. About 18% of its roughly 275 employees have experience in the sector.
That is important because space technology alone is not enough to build a pharmaceutical business. The company also needs people who understand drug research, product development, testing and the rules that apply to medicines.
Varda’s growing pharmaceutical team shows that the company sees medicine as more than a side project. It is becoming a central part of its long-term plan.
SpaceX launch changes do not hurt Varda much
The wider space market is also going through a major shift.
SpaceX has been reducing its Falcon rideshare activity. That has raised concerns among some space companies that depend on shared rocket launches to send their spacecraft into orbit.
Varda says it has less exposure to this problem than many other companies.
According to Bruey, Varda has 28 launches booked with different providers for the period from 2027 through 2029. This gives the company access to several launch options instead of relying on only one provider.
Reliable access to space is a major issue for any company that wants to build a business around orbital manufacturing.
A factory on Earth can operate every day if it has power, workers and raw materials. A factory in orbit has a much harder supply chain. It needs a rocket, a launch slot, a spacecraft and a safe route back to Earth.
Varda’s large launch schedule gives it a way to plan further ahead.
Government work remains important
Although Varda has a strong focus on medicine, government work remains a major part of its business today.
Its capsules can support hypersonic research, and this area has attracted attention from the US government.
The capsules can provide a platform for tests that require very high speeds. Their return through Earth’s atmosphere also creates an opportunity to collect data from extreme flight conditions.
This gives Varda two separate business paths. One is space-based manufacturing, with pharmaceuticals as a major target. The other is space and defense research.
Having both areas can give the company more sources of revenue as it builds its commercial business.
The space manufacturing market is still young
Varda is entering a market that is still at an early stage.
Space manufacturing has received more attention as the International Space Station moves closer to retirement in 2030. The station has served as a major place for research on how materials and biological systems behave in orbit.
Research has covered areas such as artificial organs and fiber optic materials.
Private companies now want to take some of this work beyond research and turn it into a real business. Varda is one of the companies trying to do that.
The market still has serious challenges. Launch costs remain high. Space missions are complex. A product made in orbit must also return safely to Earth.
There is another issue: not every product benefits enough from microgravity to justify the cost of space transport.
For Varda, the key question is whether the value of a space-made product can become much higher than the cost of the mission.
Investors see a large future market
The $250 million Series D deal shows that investors see enough potential in Varda’s plan to provide a large amount of new capital.
The company now has a $1.6 billion valuation and $598 million in total capital raised since its foundation in 2021.
The investment also comes at a time when private capital for space companies has grown.
A Reuters report from September 23 said private investment in space companies reached $23 billion in the year through June, more than twice the earlier level. Investors have shown more interest in companies that have real operations and a clear path toward commercial use.
Varda fits part of that shift because it already has spacecraft, completed missions and customers.
Its challenge now is to turn those technical achievements into a larger commercial business.
The next goal is commercial medicine
For Varda, the next phase will focus heavily on pharmaceuticals.
The company wants to move from government-heavy work toward a business where commercial drug companies play a much larger role. Its target is to make that change by 2032.
That shift will take more than new spacecraft. Varda will need strong partnerships with drug companies, successful research results and proof that its space-based process can create a real benefit for patients.
The company has already taken steps in this direction. Its board now has pharmaceutical expertise, and a significant part of its workforce has experience in drug development.
Its work with United Therapeutics is another example of this direction. Varda has explored the use of microgravity to create improved formulations for treatments linked to rare pulmonary disease.
A high-risk idea with a clear target
Varda’s business remains unusual. It is trying to build a factory that operates hundreds of kilometres above Earth and uses special space conditions to create valuable products.
The company has already shown that its capsules can reach orbit and return to Earth. It now needs to prove that this model can work at a larger scale and make enough commercial sense.
The $250 million Series D gives Varda more resources for that next phase. Its $1.6 billion valuation also places the company among the more valuable private space startups.
The most important test will not simply be another successful launch. The bigger test will be whether Varda can take a product from a space laboratory to a real pharmaceutical product that can move into human trials.
If that happens, the meaning of the company could change. It would no longer be only a space hardware startup. It could become a bridge between the space industry and the global pharmaceutical sector.
For now, Varda has capital, flight experience, government customers and a growing pharmaceutical team. Its next chapter will show whether those pieces can come together into a sustainable commercial business.
Also Read – SiMa.ai Raises $150M at $1.45B Valuation for AI Chips